Current clinical application of lutetium‑177 in solid tumors (Review)

Niu, Tingting; Fan, Mi; Lin, Binwei; Gao, Feng; Tan, Bangxian; Du, Xiaobo

doi:10.3892/etm.2024.12514

Cited by 3 publications

(2 citation statements)

References 77 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Lu is a long-lived (half-life of 6.7 days), β-ray emi ing (Emax = 0.49 MeV, range = 670 µm in soft tissue) radioisotope suitable for therapy. The success of 177 Lu-based radioligand therapy and peptide receptor radionuclide therapy has contributed to the growing popularity of 177 Lu as a radioisotope for radioimmunotherapy [20]. 177 Lu-PSMA has shown promising results as a treatment option for metastatic castration-resistant prostate cancer following chemotherapy and hormonal therapy [21].…”

Section: Discussionmentioning

confidence: 99%

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Preprint

View full text Add to dashboard Cite

This study investigated a novel radioimmunotherapy strategy for targeting tumor angiogenesis. We developed a radiopharmaceutical complex by labeling an anti-adenosine triphosphate syn-thase (ATPS) monoclonal antibody (mAb) with the radioisotope 177Lu using DOTA as a chelating agent. 177Lu-DOTA-ATPS mAb demonstrated high labeling efficiency (99.0%) and stability in se-rum. MKN-45 cancer cells exhibited the highest cellular uptake, which could be specifically blocked by unlabeled ATPS mAb. In mice, 177Lu-DOTA-ATPS mAb accumulated significantly in tumors, with a tumor uptake of 16.0 ± 1.5%ID/g on day 7. 177Lu-DOTA-ATPS mAb treatment sig-nificantly reduced the viability of MKN-45 cells in a dose-dependent manner. In a xenograft tumor model, this radioimmunotherapy strategy led to substantial tumor growth inhibition (82.8%). Furthermore, combining 177Lu-DOTA-ATPS mAb with sunitinib, an anti-angiogenic drug, en-hanced the therapeutic efficacy of sunitinib in the mouse model. Our study successfully developed 177Lu-DOTA-ATPS mAb, a radioimmunotherapy agent targeting tumor blood vessels. This ap-proach demonstrates significant promise for inhibiting tumor growth, both as a single therapy and in combination with other anti-cancer drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…177 Lu is a long-lived (half-life of 6.7 days), β-ray emitting (Emax = 0.49 MeV, range = 670 µm in soft tissue) radioisotope suitable for therapy. The success of 177 Lu-based radioligand therapy and peptide receptor radionuclide therapy has contributed to the growing popularity of 177 Lu as a radioisotope for radioimmunotherapy [ 20 ]. 177 Lu-PSMA has shown promising results as a treatment option for metastatic castration-resistant prostate cancer following chemotherapy and hormonal therapy [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model

Park,

An,

Kim

et al. 2024

Antibodies

View full text Add to dashboard Cite

This study investigated a novel radioimmunotherapy strategy for targeting tumor angiogenesis. We developed a radiopharmaceutical complex by labeling an anti-adenosine triphosphate synthase (ATPS) monoclonal antibody (mAb) with the radioisotope 177Lu using DOTA as a chelating agent. 177Lu-DOTA-ATPS mAb demonstrated high labeling efficiency (99.0%) and stability in serum. MKN-45 cancer cells exhibited the highest cellular uptake, which could be specifically blocked by unlabeled ATPS mAb. In mice, 177Lu-DOTA-ATPS mAb accumulated significantly in tumors, with a tumor uptake of 16.0 ± 1.5%ID/g on day 7. 177Lu-DOTA-ATPS mAb treatment significantly reduced the viability of MKN-45 cells in a dose-dependent manner. In a xenograft tumor model, this radioimmunotherapy strategy led to substantial tumor growth inhibition (82.8%). Furthermore, combining 177Lu-DOTA-ATPS mAb with sunitinib, an anti-angiogenic drug, enhanced the therapeutic efficacy of sunitinib in the mouse model. Our study successfully developed 177Lu-DOTA-ATPS mAb, a radioimmunotherapy agent targeting tumor blood vessels. This approach demonstrates significant promise for inhibiting tumor growth, both as a single therapy and in combination with other anti-cancer drugs.

show abstract

Efficient internalization of nano architectured 177Lu-hyaluronic acid@ zirconium-based metal-organic framework for the treatment of neuroblastoma: Unravelling toxicity, stability, radiolabelling and bio-distribution

Kulkarni,

Pandey,

Soman

et al. 2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Current clinical application of lutetium‑177 in solid tumors (Review)

Cited by 3 publications

References 77 publications

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

<sup>177</sup>Lu Anti-angiogenic Radioimmunotherapy Targeting ATP synthase in Gastric Cancer Model

177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model

Efficient internalization of nano architectured 177Lu-hyaluronic acid@ zirconium-based metal-organic framework for the treatment of neuroblastoma: Unravelling toxicity, stability, radiolabelling and bio-distribution

Contact Info

Product

Resources

About